Anja Hipp,
Head of CMC, VP

Anja joined Granite Bio in April 2026. She is a Swiss qualified pharmacist with a Ph. D. in medicinal chemistry from ETH Zurich. She started her career as a manager research and development at Fumapharm AG, a small Swiss Biotech company, where she coordinated CMC activities and pre-clinical research studies for an oral MS drug in late-stage development. Her role included management of multiple academic research collaborations as well as external suppliers. Anja moved to Biogen after acquisition of Fumapharm, where she held various roles with increasing responsibility in CMC development and external manufacturing. She has been responsible for clinical and commercial supply of various products and supported multiple product launches across different modalities and product stages. In her last role at Biogen, she was heading the external manufacturing biologics technology platform and was leading a team of relationship managers for strategic CDMO accounts.

Most recently, Anja has worked at different start-up companies as Head of CMC, responsible for all CMC and supply related aspects for pre-clinical oncology programs including antibody-drug conjugates, small molecules and gene therapy products. Setting up an external supplier network and contract laboratories, as well as managing relationships with alliance partners has been a key aspect of her work.